Skip to main content
Erschienen in: Pituitary 4/2012

01.12.2012

Isolated GHD: investigation and implication of JAK/STAT related genes before and after rhGH treatment

verfasst von: Letizia Trovato, Stefania Riccomagno, Flavia Prodam, Giulia Genoni, Gillian E. Walker, Stefania Moia, Simonetta Bellone, Gianni Bona

Erschienen in: Pituitary | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Isolated GH deficiency (IGHD) is a rare disorder that occurs as an idiopathic form in most cases. The pathway JAK/STAT promotes cellular growth and it could be implicated in this condition. In order to characterize IGHD in the pediatric population and identify genes differently expressed before and after GH therapy, we performed a quantitative evaluation of 84 genes related to the JAK/STAT pathway which, by promoting cellular growth. RT2 Profiler PCR Array and the other/subsequent evaluations were performed in three children with severe IGHD before and after 6 months of GH therapy and in three matched normal children. Gene profiling was modified by the IGHD status and the GH therapy, with a modulation of GHR and some inflammatory genes such as CRP. We found a heterozygous nonsense mutation R43X in the GHR gene in two out of three IGHD subjects, despite a good response to therapy. After therapy cardiovascular markers linked to genes as IL6, IL8 and TNF-α displayed a trend toward reduction. Pre- and post therapy status differently affects gene expression. Mutational screening of GHR may be useful in investigating IGHD’s etiology. Genes linked to inflammation suggest to evaluate cardiovascular risks also in pediatric IGHD subjects.
Literatur
1.
Zurück zum Zitat Hernández LM, Lee PD, Camacho-Hübner C (2007) Isolated growth hormone deficiency. Pituitary 10(4):351–357PubMedCrossRef Hernández LM, Lee PD, Camacho-Hübner C (2007) Isolated growth hormone deficiency. Pituitary 10(4):351–357PubMedCrossRef
2.
Zurück zum Zitat Alatzoglou KS, Turton JP, Kelberman D, Clayton PE, Mehta A, Buchanan C, Aylwin S, Crowne EC, Christesen HT, Hertel NT, Trainer PJ, Savage MO, Raza J, Banerjee K, Sinha SK, Ten S, Mushtaq T, Brauner R, Cheetham TD, Hindmarsh PC, Mullis PE, Dattani MT (2009) Expanding the spectrum of mutations in GH1 and GHRHR: genetic screening in a large cohort of patients with congenital isolated growth hormone deficiency. J Clin Endocrinol Metab 94(9):3191–3199PubMedCrossRef Alatzoglou KS, Turton JP, Kelberman D, Clayton PE, Mehta A, Buchanan C, Aylwin S, Crowne EC, Christesen HT, Hertel NT, Trainer PJ, Savage MO, Raza J, Banerjee K, Sinha SK, Ten S, Mushtaq T, Brauner R, Cheetham TD, Hindmarsh PC, Mullis PE, Dattani MT (2009) Expanding the spectrum of mutations in GH1 and GHRHR: genetic screening in a large cohort of patients with congenital isolated growth hormone deficiency. J Clin Endocrinol Metab 94(9):3191–3199PubMedCrossRef
3.
Zurück zum Zitat Meyer S, Ipek M, Keth A, Minnemann T, von Mach MA, Weise A, Ittner JR, Nawroth PP, Plöckinger U, Stalla GK, Tuschy U, Weber MM, Kann PH, German KIMS Board, German KIMS Pharmacogenetics Study Group (2007) Short stature and decreased insulin-like growth factor I (IGF-I)/growth hormone (GH)-ratio in an adult GH-deficient patient pointing to additional partial GH insensitivity due to a R179C mutation of the growth hormone receptor. Growth Horm IGF Res 17(4):307–314PubMedCrossRef Meyer S, Ipek M, Keth A, Minnemann T, von Mach MA, Weise A, Ittner JR, Nawroth PP, Plöckinger U, Stalla GK, Tuschy U, Weber MM, Kann PH, German KIMS Board, German KIMS Pharmacogenetics Study Group (2007) Short stature and decreased insulin-like growth factor I (IGF-I)/growth hormone (GH)-ratio in an adult GH-deficient patient pointing to additional partial GH insensitivity due to a R179C mutation of the growth hormone receptor. Growth Horm IGF Res 17(4):307–314PubMedCrossRef
4.
Zurück zum Zitat Jancevska A, Gucev ZS, Tasic V, Pop-Jordanova N (2009) Growth hormone deficiency (GHD) and small for gestational age (SGA): genetic alterations. Prilozi 30(2):33–55PubMed Jancevska A, Gucev ZS, Tasic V, Pop-Jordanova N (2009) Growth hormone deficiency (GHD) and small for gestational age (SGA): genetic alterations. Prilozi 30(2):33–55PubMed
5.
Zurück zum Zitat Rosenfeld RG, Belgorosky A, Camacho-Hubner C, Savage MO, Wit JM, Hwa V (2007) Defects in growth hormone receptor signaling. Trends Endocrinol Metab 18(4):134–141PubMedCrossRef Rosenfeld RG, Belgorosky A, Camacho-Hubner C, Savage MO, Wit JM, Hwa V (2007) Defects in growth hormone receptor signaling. Trends Endocrinol Metab 18(4):134–141PubMedCrossRef
6.
Zurück zum Zitat Lanes R (2004) Long-term outcome of growth hormone therapy in children and adolescents. Treat Endocrinol 3(1):53–66PubMedCrossRef Lanes R (2004) Long-term outcome of growth hormone therapy in children and adolescents. Treat Endocrinol 3(1):53–66PubMedCrossRef
7.
Zurück zum Zitat Jorge AA, Arnhold IJ (2009) Growth hormone receptor exon 3 isoforms and their implication in growth disorders and treatment. Horm Res 71(Suppl 2):55–63PubMedCrossRef Jorge AA, Arnhold IJ (2009) Growth hormone receptor exon 3 isoforms and their implication in growth disorders and treatment. Horm Res 71(Suppl 2):55–63PubMedCrossRef
8.
Zurück zum Zitat Ranke MB, Lindberg A (2009) Predicting growth in response to growth hormone treatment. Growth Horm IGF Res 19:1–11PubMedCrossRef Ranke MB, Lindberg A (2009) Predicting growth in response to growth hormone treatment. Growth Horm IGF Res 19:1–11PubMedCrossRef
9.
Zurück zum Zitat Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N, Klibanski A (2000) Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 133(2):111–122PubMed Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N, Klibanski A (2000) Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 133(2):111–122PubMed
10.
Zurück zum Zitat Deepak D, Daousi C, Javadpour M, Clark D, Perry Y, Pinkney J, Macfarlane IA (2010) The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency. Growth Horm IGF Res 20(3):220–225PubMedCrossRef Deepak D, Daousi C, Javadpour M, Clark D, Perry Y, Pinkney J, Macfarlane IA (2010) The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency. Growth Horm IGF Res 20(3):220–225PubMedCrossRef
11.
Zurück zum Zitat Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V, Dimaraki E, Stavrou S, Vance ML, Hayden D, Klibanski A (2002) Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab 87(4):1692–1699PubMedCrossRef Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V, Dimaraki E, Stavrou S, Vance ML, Hayden D, Klibanski A (2002) Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab 87(4):1692–1699PubMedCrossRef
12.
Zurück zum Zitat Cacciari E, Milani S, Balsamo A, Spada E, Bona G, Cavallo L, Cerutti F, Gargantini L, Greggio N, Tonini G, Cicognani A (2006) Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). J Endocrinol Invest 29(7):581–593PubMed Cacciari E, Milani S, Balsamo A, Spada E, Bona G, Cavallo L, Cerutti F, Gargantini L, Greggio N, Tonini G, Cicognani A (2006) Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). J Endocrinol Invest 29(7):581–593PubMed
13.
Zurück zum Zitat de Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT (2003) Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 10:133–139PubMed de Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT (2003) Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 10:133–139PubMed
14.
Zurück zum Zitat Andreassen M, Vestergaard H, Kristensen LØ (2007) Concentrations of the acute phase reactants high-sensitive C-reactive protein and YKL-40 and of interleukin-6 before and after treatment in patients with acromegaly and growth hormone deficiency. Clin Endocrinol (Oxf) 67(6):909–916CrossRef Andreassen M, Vestergaard H, Kristensen LØ (2007) Concentrations of the acute phase reactants high-sensitive C-reactive protein and YKL-40 and of interleukin-6 before and after treatment in patients with acromegaly and growth hormone deficiency. Clin Endocrinol (Oxf) 67(6):909–916CrossRef
15.
Zurück zum Zitat Lanes R, Marcano H, Villaroel O, Gunczler P, Morillo E, Paoli M, Perez M, Maulino N, Palacios A (2008) Circulating levels of high-sensitivity C-reactive protein and soluble markers of vascular endothelial cell activation in growth hormone-deficient adolescents. Horm Res 70(4):230–235PubMedCrossRef Lanes R, Marcano H, Villaroel O, Gunczler P, Morillo E, Paoli M, Perez M, Maulino N, Palacios A (2008) Circulating levels of high-sensitivity C-reactive protein and soluble markers of vascular endothelial cell activation in growth hormone-deficient adolescents. Horm Res 70(4):230–235PubMedCrossRef
16.
Zurück zum Zitat Szczepańska-Kostro J, Kowalewski M, Urban M, Gardziejczyk M (2006) Serum levels of matrix metalloproteinase 2 (MMP-2), matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinase 2 (TIMP-2) in children and adolescents with growth hormone deficiency. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw 12(4):257–260PubMed Szczepańska-Kostro J, Kowalewski M, Urban M, Gardziejczyk M (2006) Serum levels of matrix metalloproteinase 2 (MMP-2), matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinase 2 (TIMP-2) in children and adolescents with growth hormone deficiency. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw 12(4):257–260PubMed
17.
Zurück zum Zitat Petäjä J (2011) Inflammation and coagulation. An overview. Thromb Res 127(Suppl 2):S34–S37PubMedCrossRef Petäjä J (2011) Inflammation and coagulation. An overview. Thromb Res 127(Suppl 2):S34–S37PubMedCrossRef
18.
Zurück zum Zitat Mullis PE, O’Donovan N, Eblé A, Marti U, Diem P, Bürgi U, Peter HJ (2000) Growth hormone regulates growth hormone receptor gene transcription in primary human thyroid cells. Mol Cell Endocrinol 166(2):111–119PubMedCrossRef Mullis PE, O’Donovan N, Eblé A, Marti U, Diem P, Bürgi U, Peter HJ (2000) Growth hormone regulates growth hormone receptor gene transcription in primary human thyroid cells. Mol Cell Endocrinol 166(2):111–119PubMedCrossRef
19.
Zurück zum Zitat Bennett WL, Keeton AB, Ji S, Xu J, Messina JL (2007) Insulin regulation of growth hormone receptor gene expression: involvement of both the PI-3 kinase and MEK/ERK signaling pathways. Endocrine 32(2):219–226PubMedCrossRef Bennett WL, Keeton AB, Ji S, Xu J, Messina JL (2007) Insulin regulation of growth hormone receptor gene expression: involvement of both the PI-3 kinase and MEK/ERK signaling pathways. Endocrine 32(2):219–226PubMedCrossRef
20.
Zurück zum Zitat Amselem S, Sobrie ML, Duquesnoy P, Rappaport R, Postel-Vinay MC, Gourmelen M, Dallapiccola B, Goossens M (1991) Recurrent nonsense mutations in the Growth Hormone Receptor from patients with Laron Dwarfism. J Clin Invest 87:1098–1102PubMedCrossRef Amselem S, Sobrie ML, Duquesnoy P, Rappaport R, Postel-Vinay MC, Gourmelen M, Dallapiccola B, Goossens M (1991) Recurrent nonsense mutations in the Growth Hormone Receptor from patients with Laron Dwarfism. J Clin Invest 87:1098–1102PubMedCrossRef
21.
Zurück zum Zitat Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V, Bougnères P (2004) A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet 36(7):720–724PubMedCrossRef Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V, Bougnères P (2004) A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet 36(7):720–724PubMedCrossRef
22.
Zurück zum Zitat Barbosa EJ, Palming J, Glad CA, Filipsson H, Koranyi J, Bengtsson BA, Carlsson LM, Boguszewski CL, Johannsson G (2009) Influence of the exon 3-deleted/full-length growth hormone (GH) receptor polymorphism on the response to GH replacement therapy in adults with severe GH deficiency. J Clin Endocrinol Metab 94(2):639–644PubMedCrossRef Barbosa EJ, Palming J, Glad CA, Filipsson H, Koranyi J, Bengtsson BA, Carlsson LM, Boguszewski CL, Johannsson G (2009) Influence of the exon 3-deleted/full-length growth hormone (GH) receptor polymorphism on the response to GH replacement therapy in adults with severe GH deficiency. J Clin Endocrinol Metab 94(2):639–644PubMedCrossRef
23.
Zurück zum Zitat Räz B, Janner M, Petkovic V, Lochmatter D, Eblé A, Dattani MT, Hindmarsh PC, Flück CE, Mullis PE (2008) Influence of growth hormone (GH) receptor deletion of exon 3 and full-length isoforms on GH response and final height in patients with severe GH deficiency. J Clin Endocrinol Metab 93(3):974–980PubMedCrossRef Räz B, Janner M, Petkovic V, Lochmatter D, Eblé A, Dattani MT, Hindmarsh PC, Flück CE, Mullis PE (2008) Influence of growth hormone (GH) receptor deletion of exon 3 and full-length isoforms on GH response and final height in patients with severe GH deficiency. J Clin Endocrinol Metab 93(3):974–980PubMedCrossRef
24.
Zurück zum Zitat Pilotta A, Mella P, Filisetti M, Felappi B, Prandi E, Parrinello G, Notarangelo LD, Buzi F (2006) Common polymorphisms of the growth hormone (GH) receptor do not correlate with the growth response to exogenous recombinant human GH in GH-deficient children. J Clin Endocrinol Metab 91(3):1178–1180PubMedCrossRef Pilotta A, Mella P, Filisetti M, Felappi B, Prandi E, Parrinello G, Notarangelo LD, Buzi F (2006) Common polymorphisms of the growth hormone (GH) receptor do not correlate with the growth response to exogenous recombinant human GH in GH-deficient children. J Clin Endocrinol Metab 91(3):1178–1180PubMedCrossRef
25.
Zurück zum Zitat Ihara K, Inuo M, Kuromaru R, Miyako K, Kohno H, Kinukawa N, Hara T (2007) The Leu544Ile polymorphism of the growth hormone receptor gene affects the serum cholesterol levels during GH treatment in children with GH deficiency. Clin Endocrinol (Oxf) 67(2):212–217CrossRef Ihara K, Inuo M, Kuromaru R, Miyako K, Kohno H, Kinukawa N, Hara T (2007) The Leu544Ile polymorphism of the growth hormone receptor gene affects the serum cholesterol levels during GH treatment in children with GH deficiency. Clin Endocrinol (Oxf) 67(2):212–217CrossRef
26.
Zurück zum Zitat Lanes R (2004) Metabolic abnormalities in growth hormone deficiency. Pediatr Endocrinol Rev 2(2):209–215PubMed Lanes R (2004) Metabolic abnormalities in growth hormone deficiency. Pediatr Endocrinol Rev 2(2):209–215PubMed
27.
Zurück zum Zitat Lanes R, Soros A, Flores K, Gunczler P, Carrillo E, Bandel J (2005) Endothelial function, carotid artery intima-media thickness, epicardial adipose tissue, and left ventricular mass and function in growth hormone-deficient adolescents: apparent effects of growth hormone treatment on these parameters. J Clin Endocrinol Metab 90(7):3978–3982PubMedCrossRef Lanes R, Soros A, Flores K, Gunczler P, Carrillo E, Bandel J (2005) Endothelial function, carotid artery intima-media thickness, epicardial adipose tissue, and left ventricular mass and function in growth hormone-deficient adolescents: apparent effects of growth hormone treatment on these parameters. J Clin Endocrinol Metab 90(7):3978–3982PubMedCrossRef
Metadaten
Titel
Isolated GHD: investigation and implication of JAK/STAT related genes before and after rhGH treatment
verfasst von
Letizia Trovato
Stefania Riccomagno
Flavia Prodam
Giulia Genoni
Gillian E. Walker
Stefania Moia
Simonetta Bellone
Gianni Bona
Publikationsdatum
01.12.2012
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 4/2012
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-011-0354-8

Weitere Artikel der Ausgabe 4/2012

Pituitary 4/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.